Conclusion: Rasagiline is an investigational selective and irreversible inhibitor of MAO-B that has demonstrated efficacy and safety for the treatment of PD. Whether rasagiline is associated with ...

Healthcare providers may prescribe levodopa, dopamine agonists, anticholinergics, catechol-o-methyltransferase (COMT) ...

Ebersbach and Warnecke point out the classification of MAO-B inhibitors as “potentially inadequate medication” (PIM) and the naming of ropinirole as an alternative. The cited study included ...

The following evaluations of anti-Parkinson medications are partly implausible and misleading: All MAO-B inhibitors are classified as PIM and recommended as an alternative to the dopamine agonist ...

a MAO-B = monoamine oxidase type B, MAO-A = monoamine oxidase type A. b Expressed as the molar concentration of drug required to inhibit enzyme activity by 50% (nmol/L). c Expressed as the ...